Literature DB >> 7745821

Evaluation of the effect of pancreatic resection in advanced pancreatic cancer with special reference using hospital-free survival as a measure of quality of life.

M Yasue1, J Sakamoto, T Morimoto, K Yasui, N Kuno, K Kurimoto, S Teramukai, Y Ohashi.   

Abstract

Comparisons of surgical procedures and the identification of prognostic factors in pancreatic cancer were carried out on 158 patients who underwent surgery in Aichi Cancer Center from 1975 to 1991 for advanced pancreatic ductal adenocarcinoma. Survival and 'hospital-free survival (HFS), which we consider the best general means of measuring quality of life (QOL) in such severe and often fatal disease, were identified as primary end points, and the effect of pancreatectomy, compared with palliative surgery (by-pass operation, etc.) for TNM Stages III and IV pancreatic cancer was evaluated. Both survival and HFS were significantly longer in the group of patients who underwent pancreatectomies (R group, n 25) compared to the group without pancreatic resection (NR group, n 35) in Stage III cases. In Stage IV cases, however, no significant difference was observed between the R (n 12) and NR (n 86) groups. From these results, we conclude that an extensive pancreatic resection against Stage III pancreatic cancer may improve prognosis. For Stage IV pancreatic cancers, however, aggressive surgery might not always be beneficial either for survival or for QOL.

Entities:  

Mesh:

Year:  1995        PMID: 7745821

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  2 in total

Review 1.  Pancreatic adenocarcinoma: why and when should it be resected?

Authors:  D Ravichandran; C D Johnson
Journal:  Postgrad Med J       Date:  1997-08       Impact factor: 2.401

2.  Assessment of peri-operative quality of life in patients undergoing surgery for gastrointestinal cancer.

Authors:  Toshiko Matsushita; Eisuke Matsushima; Michio Maruyama
Journal:  Support Care Cancer       Date:  2004-04-03       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.